The National Institutes of Health (NIH) announced yesterday that it is issuing nearly $32 million in grants for the development of strategies to analyze and leverage biomedical data sets.
The National Institutes of Health (NIH) announced yesterday that it is issuing nearly $32 million in grants for the development of strategies to analyze and leverage biomedical data sets. The grants are part of NIH’s Big Data to Knowledge (BD2K) initiative, launched in December 2013. BD2K is funded from all 27 NIH institutes and centers, as well as the NIH Common Fund.
According to NIH, the collection of data from biomedical research, including DNA sequencing and imaging, is increasing beyond researchers’ ability to use the data. NIH intends for the BD2K awards to “support the development of new approaches, software, tools, and training programs to improve access to these data and the ability to make new discoveries using them.”
“Data creation in today’s research is exponentially more rapid than anything we anticipated even a decade ago,” said NIH Director Francis S. Collins, MD, PhD, in a press release. “Mammoth data sets are emerging at an accelerated pace in today’s biomedical research and these funds will help us overcome the obstacles to maximizing their utility. The potential of these data, when used effectively, is quite astounding.”
NIH funding will establish 12 centers that will each tackle specific data science challenges and provide support for creating a scientific community-based consortium to develop approaches for the creation of a data discovery index, data science training, and workforce development. The centers will be set up as follows:
More information about the recipients of the new grants may be found on NIH’s website at http://bd2k.nih.gov/FY14.html.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.